FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306321330> ?p ?o ?g. }

• W4306321330 endingPage "S316" @default.
• W4306321330 startingPage "S316" @default.
• W4306321330 abstract "Philadelphia chromosome is found in less than 5% of pediatric but in more than 20% of adults patients with acute lymphoblastic leukemia (ALL). The advent of tyrosine kinase inhibitors (TKIs) lead to a dramatic improvement in the prognosis of these patients, who now have the same stem cell transplantation (SCT) indications as other ALL patients. Recommendations regarding the choice between prophylactic or preemptive strategy, duration of use and the best type of TKI post-SCT need to be better defined. Here we aimed to report a Ph+ ALL pediatric case and to discuss TKI management after SCT. An 9-year-old boy, diagnosed with hyperleukocytic Ph+ B-ALL,mutated IKZF1 and negative CNS was treated according to EsPhALL 2010 protocol. He was poor steroid responder on D8, started imatinib on D14, had 30% of blasts on D15 and 0,4% on D33, persistent positive MRD 0.14% by flow cytometry on week 12. Thus, he was classified as high risk, with allogeneic SCT indication in first remission. He received a 10/10 HLA-matched unrelated SCT from an ABO compatible, male, cytomegalovirus positive donor, with cyclophosphamide, total body irradiation and thymoglobulin for conditioning and cyclosporine plus methotrexatefor graft-versus-host disease prophylaxis. Prophylatic imatinib (100 mg/day) started on D+63 post-SCT. Nevertheless, molecular relapse occurred on D+170. Imatinib was replaced by dasatinib (60 mg/day) and he received three donor lymphocytes infusions (DLI), achieving molecular remission. Due to the occurrence of hematochezia and cytopenias a short suspension and subsequent dose reduction of dasatinib was necessary, after that, he tolerated well 20 mg/day for seven months. After three negative MRD, dasatinib was suspended. Ten months after dasatinib withdrawal, he had an isolated hematological relapse (51% of blasts), at two years post-SCT. He received dexamethasone and dasatinib for cytoreduction followed by IntReALL protocol with hematological remission, but MRD remained positive. Dasatinib was maintained without complications. He received two cycles of blinatumomab, achieving molecular remission. He underwent a second SCT with haploidentical donor in third complete remission. However, he developed severe hepatic venoocclusive disease (VOD) and died on D+48. Several issues related to the TKI usage post-SCT for Ph+ ALL has to be elucidate. The EBMT recommendation of prophylactic imatinib use after SCT,was based on lower relapse rate and better survival reported by a retrospective study in adults patients with imatinib. More recently, a systematic review showed that both prophylactic and preemptive TKIs approaches post-SCT improved survival of patients in CR1 before transplant. Thus, the choice ofpreemptiveuse of TKIs seems to be reasonable, since is less toxic and less immunosuppressive; however, it require a more frequent MRD monitoring by flow cytometry or IgH/TCR PCR and TKIs maintenance until at least one year after MRD negativity. : Our case illustrates the efficacy of dasatinib preemptive associated with DLI in inducing molecular remission. However, it points out that, in addition to the extension of the marrow MRD monitoring period, the duration of TKI use to guarantee the persistence of molecular remission can be long, for more than one year since MRD negativity." @default.
• W4306321330 created "2022-10-16" @default.
• W4306321330 creator A5001378398 @default.
• W4306321330 creator A5007180634 @default.
• W4306321330 creator A5018567924 @default.
• W4306321330 creator A5022979311 @default.
• W4306321330 creator A5035783968 @default.
• W4306321330 creator A5040497078 @default.
• W4306321330 creator A5055464335 @default.
• W4306321330 creator A5065333090 @default.
• W4306321330 creator A5069800605 @default.
• W4306321330 creator A5074465924 @default.
• W4306321330 date "2022-10-01" @default.
• W4306321330 modified "2023-09-26" @default.
• W4306321330 title "TYROSINE KINASE INHIBITORS MANAGEMENT AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PH+ ALL: LESSONS FROM A PEDIATRIC CHALLENGING CASE" @default.
• W4306321330 doi "https://doi.org/10.1016/j.htct.2022.09.535" @default.
• W4306321330 hasPublicationYear "2022" @default.
• W4306321330 type Work @default.
• W4306321330 citedByCount "0" @default.
• W4306321330 crossrefType "journal-article" @default.
• W4306321330 hasAuthorship W4306321330A5001378398 @default.
• W4306321330 hasAuthorship W4306321330A5007180634 @default.
• W4306321330 hasAuthorship W4306321330A5018567924 @default.
• W4306321330 hasAuthorship W4306321330A5022979311 @default.
• W4306321330 hasAuthorship W4306321330A5035783968 @default.
• W4306321330 hasAuthorship W4306321330A5040497078 @default.
• W4306321330 hasAuthorship W4306321330A5055464335 @default.
• W4306321330 hasAuthorship W4306321330A5065333090 @default.
• W4306321330 hasAuthorship W4306321330A5069800605 @default.
• W4306321330 hasAuthorship W4306321330A5074465924 @default.
• W4306321330 hasBestOaLocation W43063213301 @default.
• W4306321330 hasConcept C104317684 @default.
• W4306321330 hasConcept C121608353 @default.
• W4306321330 hasConcept C126322002 @default.
• W4306321330 hasConcept C138626823 @default.
• W4306321330 hasConcept C143998085 @default.
• W4306321330 hasConcept C185592680 @default.
• W4306321330 hasConcept C203014093 @default.
• W4306321330 hasConcept C2777408962 @default.
• W4306321330 hasConcept C2777583451 @default.
• W4306321330 hasConcept C2777630719 @default.
• W4306321330 hasConcept C2778729363 @default.
• W4306321330 hasConcept C2778820342 @default.
• W4306321330 hasConcept C2778904597 @default.
• W4306321330 hasConcept C2779536868 @default.
• W4306321330 hasConcept C28328180 @default.
• W4306321330 hasConcept C2909675724 @default.
• W4306321330 hasConcept C2911091166 @default.
• W4306321330 hasConcept C54355233 @default.
• W4306321330 hasConcept C55493867 @default.
• W4306321330 hasConcept C71924100 @default.
• W4306321330 hasConcept C86803240 @default.
• W4306321330 hasConcept C90924648 @default.
• W4306321330 hasConceptScore W4306321330C104317684 @default.
• W4306321330 hasConceptScore W4306321330C121608353 @default.
• W4306321330 hasConceptScore W4306321330C126322002 @default.
• W4306321330 hasConceptScore W4306321330C138626823 @default.
• W4306321330 hasConceptScore W4306321330C143998085 @default.
• W4306321330 hasConceptScore W4306321330C185592680 @default.
• W4306321330 hasConceptScore W4306321330C203014093 @default.
• W4306321330 hasConceptScore W4306321330C2777408962 @default.
• W4306321330 hasConceptScore W4306321330C2777583451 @default.
• W4306321330 hasConceptScore W4306321330C2777630719 @default.
• W4306321330 hasConceptScore W4306321330C2778729363 @default.
• W4306321330 hasConceptScore W4306321330C2778820342 @default.
• W4306321330 hasConceptScore W4306321330C2778904597 @default.
• W4306321330 hasConceptScore W4306321330C2779536868 @default.
• W4306321330 hasConceptScore W4306321330C28328180 @default.
• W4306321330 hasConceptScore W4306321330C2909675724 @default.
• W4306321330 hasConceptScore W4306321330C2911091166 @default.
• W4306321330 hasConceptScore W4306321330C54355233 @default.
• W4306321330 hasConceptScore W4306321330C55493867 @default.
• W4306321330 hasConceptScore W4306321330C71924100 @default.
• W4306321330 hasConceptScore W4306321330C86803240 @default.
• W4306321330 hasConceptScore W4306321330C90924648 @default.
• W4306321330 hasLocation W43063213301 @default.
• W4306321330 hasOpenAccess W4306321330 @default.
• W4306321330 hasPrimaryLocation W43063213301 @default.
• W4306321330 hasRelatedWork W1979064155 @default.
• W4306321330 hasRelatedWork W1994309500 @default.
• W4306321330 hasRelatedWork W2013963600 @default.
• W4306321330 hasRelatedWork W2025416101 @default.
• W4306321330 hasRelatedWork W2093585213 @default.
• W4306321330 hasRelatedWork W2112405804 @default.
• W4306321330 hasRelatedWork W2151238788 @default.
• W4306321330 hasRelatedWork W2944597979 @default.
• W4306321330 hasRelatedWork W4225349281 @default.
• W4306321330 hasRelatedWork W4246110794 @default.
• W4306321330 hasVolume "44" @default.
• W4306321330 isParatext "false" @default.
• W4306321330 isRetracted "false" @default.
• W4306321330 workType "article" @default.